WO2003076928A1 - Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis - Google Patents
Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis Download PDFInfo
- Publication number
- WO2003076928A1 WO2003076928A1 PCT/US2003/007103 US0307103W WO03076928A1 WO 2003076928 A1 WO2003076928 A1 WO 2003076928A1 US 0307103 W US0307103 W US 0307103W WO 03076928 A1 WO03076928 A1 WO 03076928A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- genes
- subset
- pluralities
- cells
- identifying
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/30—Microarray design
Definitions
- the present invention relates in general to statistical analysis of microarray data generated from nucleotide arrays. Specifically, the present invention relates to identification of differentially expressed genes by multivariate microarray data analysis. More specifically, the present invention provides an improved multivariate random search method for identifying large sets of genes that are differentially expressed under a given biological state or at a given biological locale of interest according to the values of a probability distance calculated for numerous subsets of genes. The method of the invention provides a successive elimination procedure to remove smaller subsets resulted from each step of the random search thereby establishing a larger set of differentially expressed genes.
- Gene expression analyses based on microarray data promises to open new avenues for researchers to unravel the functions and interactions of genes in various biological pathways and, ultimately, to uncover the mechanisms of life in diversified species.
- a significant objective in such expression analyses is to identify genes that are differentially expressed in different cells, tissues, organs of interest or at different biological states. So identified, a set of differentially expressed genes associated with a certain biological state, e.g., tumor or certain pathology, may point to the cause of such tumor or pathology, and thereby shed light on the search of potential cures.
- differentially expressed genes are typically univariate, not taking into account the information on interactions among genes.
- genes do not operate in isolation - activation of one gene may trigger changes in the expression levels of other genes. That is, genes may be involved in one or more pathways or networks. Therefore, determination of differentially expressed genes calls for consideration of covariance structure of the microarray data, in addition to, for example, mean expression levels.
- application of well-established statistical techniques for multidimensional variable selection encounters much difficulty. This is so because, in one aspect, the small number of independent samples and the presence of outliers make the estimates on selected variables unstable for large dimensions.
- identifying a set of genes from a multiplicity of genes whose expression levels at a first and a second state, in a first and a second tissue, or in a first and a second types of cells are measured in replicates using one or more nucleotide arrays, thereby generating a first plurality of independent measurements of the expression levels for the first state, tissue, or type of cells and a second plurality of independent measurements of the expression levels for the second state, tissue, or type of cells.
- the methods comprise: (a) identifying a quality function capable of evaluating the distinctiveness between the first plurality and the second plurality; (b) forming a first predetermined number of permutations from the first and the second pluralities, dividing the permutations into a first permutated plurality and a second permutated plurality, corresponding in size, to the first and second plurality, respectively, and identifying groups of genes the size of which is a second predetermined number, wherein the values of the quality function for the group of genes in the first permutated and second permutated pluralities attain the maximum; (c) determining, from the first and second permutated pluralities, the top ⁇ th percentile of the null distribution based on a quantitative characteristic of the groups of genes; (d) identifying, based on the first and second pluralities, a subset of genes the size of which is the second predetermined number, wherein the values of the quality function for the subset of genes in the first and second pluralities attain the maximum; (e) adding to the set of genes,
- the states may be biological states, physiological states, pathological states, and prognostic states.
- the tissues may be normal lung tissues, cancer lung tissues, normal heart tissues, pathological heart tissues, normal and abnormal colon tissues, normal and abnormal renal tissues, normal and abnormal prostate tissues, and normal and abnormal breast tissues.
- the types of cells may be normal lung cells, cancer lung cells, normal heart cells, pathological heart cells, normal and abnormal colon cells, normal and abnormal renal cells, normal and abnormal prostate cells, and normal and abnormal breast cells.
- the types of cells may be cultured cells and cells isolated from an organism.
- the quality function is represented by a probability distance between random vectors.
- the probability distance function is selected from the group consisting of the Mahalanobis distance and the Bhattacharya distance.
- the negative definite kernel is combined with the Euclidean distance between x and y to form a composite kernel function.
- the quantitative characteristic is selected from the group consisting of an associated probability distance, a test set classification rate, and a cross-validation classification rate.
- the formation of the permutations further comprises: (i) shifting the measurements in the first and second pluralities such that the marginal means thereof share the same true mean; and (ii) randomly permuting the resulting shifted measurements thereby forming a null-distribution of permutations.
- the identifying further comprises: (i) calculating the values of the quality function for the subset of genes in the first and second pluralities thereby evaluating the distinctiveness of the first and second pluralities; and (ii) substituting a gene in the subset with one outside of the subset, thereby generating a new subset, and repeating step (i), keeping the new subset if the distinctiveness increases and the original subset if otherwise; and (iii) repeating steps (i) and (ii) for a fourth predetermined number of times.
- the identifying further comprises: (i) randomly dividing the first and the second pluralities into v groups of an approximate equal size; (ii) removing one of the v groups from the first and second pluralities and identifying, from the resulting reduced first and second pluralities, a subset of genes for which the value of the quality function attains the maximum; and (iii) repeating step (ii) for each of the v groups thereby obtaining v subsets of genes.
- the nucleotide arrays may be arrays having spotted thereon cDNA sequences and/or arrays having synthesized thereon oligonucleotides.
- Fig. 1 shows the properties of the optimal subsets of genes identified in a computer simulation study using a random search method with a successive elimination procedure according to one embodiment of the invention.
- Fig. 2 shows the properties of the optimal subsets of genes identified in an expression analysis of colon cancer cells using a random search procedure with a successive elimination procedure according to one embodiment of the invention.
- Fig. 3 shows the estimates of the null-distributions based on the associated probability distance (the top panel), the test set classification rate (the bottom panel, the curve on the left), and the cross validation classification rate (the bottom panel, the curve on the right) for the 5-element optimal subset of genes in a "no-difference" dataset generated by a resampling procedure according to one embodiment of the invention.
- microarray refers to nucleotide arrays; “array,” “slide,” and “chip” are used interchangeably in this disclosure.
- Various kinds of nucleotide arrays are made in research and manufacturing facilities worldwide, some of which are available commercially. There are, for example, two kinds of arrays depending on the ways in which the nucleic acid materials are spotted onto the array substrate: oligonucleotide arrays and cDNA arrays.
- One of the most widely used oligonucleotide arrays is GeneChip made by Affymetrix, Inc. The oligonucleotide probes that are 20- or 25-base long are synthesized in silico on the array substrate.
- cDNA arrays tend to achieve high densities (e.g., more than 40,000 genes per cm 2 ).
- the cDNA arrays tend to have lower densities, but the cDNA probes are typically much longer than 20- or 25-mers.
- a representative of cDNA arrays is LifeArray made by Incyte Genomics. Pre-synthesized and amplified cDNA sequences are attached to the substrate of these kinds of arrays.
- Microarray data encompasses any data generated using various nucleotide arrays, including but not limited to those described above.
- microarray data includes collections of gene expression levels measured using nucleotide arrays on biological samples of different biological states and origins.
- the methods of the present invention may be employed to analyze any microarray data; irrespective of the particular microarray platform from which the data are generated.
- Gene expression refers to the transcription of DNA sequences, which encode certain proteins or regulatory functions, into RNA molecules.
- the expression level of a given gene refers to the amount of RNA transcribed therefrom measured on a relevant or absolute quantitative scale. The measurement can be, for example, an optic density value of a fluorescent or radioactive signal, on a blot or a microarray image.
- Differential expression means that the expression levels of certain genes are different in different states, tissues, or type of cells, according to a predetermined standard. Such standard maybe determined based on the context of the expression experiments, the biological properties of the genes under study, and/or certain statistical significance criteria.
- vector means "probability distance,” “distance,” “the Mahalanobis distance,” “the Euclidean distance,” “feature,” “feature space,” “dimension,” “space,” “type I error,” “type II error,” “ROC curve,” “permutation,” “random permutation,” and “null distribution” are to be understood consistently with their typical meanings established in the relevant art, i.e. the art of mathematics, statistics, and any area related thereto.
- two tissues, types of cells, or biological states are of interest, one of which corresponds to the normal physiology while the other implicates certain pathology such as tumor.
- the distinctiveness of these two tissues, types of cells, or states can be evaluated by microarray experiments in which the expression levels of all the genes (up to thousands measured on a single chip or slide as made possible by the recent advances in the microarray manufacturing) are determined.
- a collection of differentially expressed genes would therefore account, at the genomic/genetic level, for the distinctiveness of the two tissues, type of cells, or states. Certain multivariate distances are employed to evaluate such distinctiveness according to this invention.
- a probability distance and its nonparametric estimate may be used in this context.
- Let ⁇ and v be two probability measures defined on the Euclidean space.
- L(xy) be a strictly negative definite kernel, that is ⁇ s .
- a probability distance N( ⁇ , v) is a metric in the space of all probability measures on R d .
- N( ⁇ ,v) 2 [ rf j Rd L(x,y)d ⁇ (x)d v(y) - rf ⁇ L(x,y)d ⁇ (x)d ⁇ (y) - ⁇ d L(x,y)d v(x)d v(y)
- N( ⁇ ,v) 2 [ rf j Rd L(x,y)d ⁇ (x)d v(y) - rf ⁇ L(x,y)d ⁇ (x)d ⁇ (y) - ⁇ d L(x,y)d v(y)d v(y)
- a pertinent kernel function L needs to be chosen when the probability distance N( ⁇ , v) is used. Appropriate choices include the Euclidean distance between ranks and a monotone function of the Euclidean distance satisfying the condition of negative definiteness. Additionally, an alternative class of kernel functions may be used to measure pairwise gene interaction.
- L x,y) max(f(x)J ⁇ y))
- L f is a negative definite kernel.
- Negative definite kernels of the type described above may be combined with the usual Euclidean distance to form composite kernel functions. For example, define a region function (here denotes the floor function, its value is the largest integer not exceeding the argument and q > 2 is an integer parameter). This function is constant on each of the q obtained by dividing the sides of the (0,1) 2 into q equal segments. Then the following kernels on the ranked data may be defined:
- the second component of the kernel will be insensitive to perturbation, yet pick up sets of genes that have similar expression levels across samples in one tissue and different expression patterns in the two tissues.
- x" and y" denote normalized data such that the tissue-specific sample mean and variance are zero and one respectively.
- f g g (x") x g " x g " .
- the weights W ⁇ and w 2 may be chosen to balance the contribution of the two components.
- a distance based on L 3 will tend to pick up sets of genes with separated means and differences in correlation in the two samples.
- an aforementioned multivariate distance may be used to search for a subset(s) of genes that are differentially expressed between the two tissues, types of cells, or biological states as the corresponding values of the distance are maximized.
- the size of such subsets is predetermined, which are typically small since they are limited by the available sample replicates. In theory, all subsets of a predetermined size need to be evaluated in terms of the adopted distance and the one that provides a maximum distance should be chosen as the final set of differentially expressed genes.
- step 2 in succession for each of the groups, obtaining v optimal subsets.
- multiple local searches may be performed and then the resulting locally sub-optimal subsets may be integrated such that a final set of differentially expressed genes may be identified (e.g., by including the genes with the highest frequency of occurrences in the locally sub-optimal subsets).
- random search procedures based on certain probability distances may be utilized to identify a subset of differentially expressed genes of a predetermined size.
- a predetermined size as such often is limited by the scarcity of the sample size (especially when the total number of genes is large and the dimensionality of the microarray data is high), it is desirable to find a way to enlarge the size of the set of differentially expressed genes identified.
- a successive selection procedure is adopted to eliminate groups of genes after each run of the random search procedure, until no more subsets of genes can be found that satisfy the search criteria.
- the final set of differentially expressed genes would then include all the removed genes at each step.
- Essential to this method is the formulation of a stopping rule at each step.
- the formulation of such an appropriate stopping rule turns on the evaluation of the properties of an optimal set of genes in a "no-difference" data set.
- Various quality functions may be used in this context to provide a model to evaluate such properties. For example, certain multivariate distances are used as the quality function in various embodiment of this invention.
- the selection process based on the application of such multivariate quality functions would necessarily be influenced by the covariance structure of the microarray data.
- the "no-difference" baseline data i.e., corresponding to the null-distribution
- the first step ensures that the marginal means of the two data sets (may have been obtained from two tissues, types of cells, or biological states) have the same true mean. And, the second step mimics the biological variability through permutation.
- the null-distributions of various quantitative characteristics of the optimal gene set may be estimated. For example, the associated probability distance, cross validation classification rate (using a selected subset upon cross validation), and test set classification rate (using an independent test set) may be considered.
- a test set classification rate is calculated by classifying each sample from an independent test set using the selected subset of genes and the entire training set and determining the rate of the correct classification.
- a cross-validation classification rate is calculated by classifying each sample in the training set (in the absence of a test set) using the selected subset of genes and the rest of the training set and determining the rate of the correct classification.
- the test set classification rate may be most desirable but, due to the scarcity of samples, an appropriate test set is often unavailable. In such situations, the between-tissue distance associated with gene sets may be a good and stable proxy for the classification rate.
- a probability distance-based successive-selection procedure is adopted in selecting a subset of genes that are differentially expressed in two tissues, type of cells, or biological states, as outlined below (Procedure 3).
- the successive selection based on cross- validation or test set classification rates may be similarly adopted in connection with random searches in alternative embodiments of this invention.
- step 2 find the k-element optimal set of genes for which the associated probability distance attains its maximum and denote it by Gj . If the associated probability distance D(G 1 )> D a , then continue, otherwise stop the search. 3. In the t th iteration, discard sets G h ..., G t . ⁇ and find the k-element optimal set G t from the remaining genes. If the associated distance D(G ⁇ )> D a , then continue with this step (next iteration), otherwise proceed to step 4.
- a simulation study was performed to evaluate the improved random search method with the successive elimination procedure.
- a total of 1000 genes was divided into subsets of equal size 20.
- no differential expression was imposed, and hence any difference shown would be due to the within-tissue "biological variability.”
- the second data set one of the subsets (including 20 mutually dependent expression signals) was set to be differentially expressed with a ratio of two.
- the correlation structure was kept the same in the two data sets.
- an independent test set of 100 observations was simulated for the two data sets in order to estimate the true classification rate of the selected gene sets.
- M was set at 100,000.
- the Euclidean distance was chosen for the kernel L(x, y) in the distance measure.
- the tissue classification rate was estimated using both cross validation (using the selected gene set) and the independent test set. The results are shown in Fig. 1.
- the top panel shows the results for the data set that had no difference imposed whereas the bottom panel shows the results for the data set that had a subset of 20 genes to be differentially expressed in the two hypothetical tissues.
- the left y axis represents the associated probability distance while the right y axis denotes the classification rate based on the independent test set (hence test set classification rate - "Class") and the classification rate based on cross validation using selected gene set (hence cross validation classification rate - "CN").
- the x axis of both panel denotes the number of subsets of genes with a predetermined size of 5. As shown in both panels of Fig.
- the selection should stop after 4 iterations (i.e., to identify 4 subsets of 5 genes).
- the distance curve (Dist) passes its cutoff level after the third iteration, whereas the cross validation and the test set classification curves pass their cutoff levels after the fourth iteration.
- the successive elimination procedures based on associated distance, the test set classification rate, as well as the cross validation classification rate all performed satisfactorily in this simulation, with the distance-based procedure slightly inferior to the other two as it stopped early.
- the distance-based procedure demonstrated superior stability and therefore it remains a powerful alternative in certain embodiments of this invention.
- the differentially expressed genes were marked with stars in the bottom panel of Fig 1. The invention is further described by the following examples, which are illustrative of the invention but do not limit the invention in any manner.
- Example 1 a Source Code Segment Implementing Successive Selection and Re-sampling unit FExclude; interface uses
- Label 1 TLabel
- RunEliminationButton TButton; ExcludeResult: TStringAlignGrid;
- Label2 TLabel
- ClasslBox TEnhComboBox
- Class2Box TEnhComboBox
- HOButton TButton
- Label3 TLabel
- ExcludePB TProgressBar
- RandomClusterButton TButton
- RunFromDiffClButton TButton; procedure RunEliminationButtonClick(Sender: TObject); procedure Fo ⁇ nCreate(Sender: TObject); procedure SaveButtonClick(Sender: TObject); procedure ExcludeResultKeyDown(Sender: TObject; var Key: Word;
- PermMatl, PermMat2 TMatrix
- RandDistCurves, ClassCurves, RandCV TMatrix
- GeneList.CommaText DiffClusterForm.OutputMemo.Text
- llength GeneList.Count
- nelem Tranc(DiffClusterForm.NumElemInput. Value)
- nsteps Trunc(llength/nelem)
- ExcludeResult.RowCount: nsteps+1
- testset (FileExists(ClasslBox.Text)) and (FileExists(Class2Box.Text));
- HT29 cells represent advanced, highly aggressive colon tumors. They contain mutations in both the APC gene and p53 gene, two tumor suppressor genes that frequently mutate during colon tumori genesis. HCT116 cells manifest less aggressive colon tumors and harbor functional p53 and APC. They are defective in DNA repair.
- the experiment was performed with three RNA samples (1 ⁇ g RNA each). Cy-3-dCTP (green) was used to label HCT116 cells while Cy-5-dCTP (red) was used for HT29 cells. Six independent replicates were obtained each for HT29 and HCT116 cell lines. In addition, the data from a separate experiment was used as the independent test set, which contained eight replicates for each cell line.
- the left y axis represents the associated probability distance while the right y axis denotes the classification rate based on the independent test set (hence test set classification rate - "Class") and the classification rate based on cross validation using selected gene set (hence cross validation classification rate - "CN").
- the x axis denotes the number of subsets of genes with a predetermined size of 5.
- the dotted horizontal lines represent the level of the 99th percentile of the null-distributions of the corresponding measures (i.e., the associated probability distance, the test set classification rate, and the cross validation classification rate); they were estimated by generating 300 random permutation samples that mimic "no- difference" data in accordance with Procedure 2 supra.
- the cross validation rate approach stops at the 57th subset and the distance-based criteria stops at 56th subset (referring to the black diamonds on the solid lines "CN" and "Dist” in Fig. 2).
- the smoothed (via isotonic regression as discussed supra) test set classification rate drops below the cutoff much earlier, at the 12th subset (referring to the black diamond on the solid line "Class” in Fig. 2).
- the stopping points for all three measures were at closer vicinity relative to one other.
- the extremely high variability of the test set classification rate may be responsible for such discrepancy, since the test set data was generated in a separate and earlier experiment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Molecular Biology (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002478605A CA2478605A1 (en) | 2002-03-07 | 2003-03-07 | Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis |
AU2003213786A AU2003213786A1 (en) | 2002-03-07 | 2003-03-07 | Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis |
US10/506,767 US20060088831A1 (en) | 2002-03-07 | 2003-03-07 | Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis |
EP03711477A EP1488228A4 (en) | 2002-03-07 | 2003-03-07 | Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36208702P | 2002-03-07 | 2002-03-07 | |
US60/362,087 | 2002-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003076928A1 true WO2003076928A1 (en) | 2003-09-18 |
Family
ID=27805126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/007103 WO2003076928A1 (en) | 2002-03-07 | 2003-03-07 | Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060088831A1 (en) |
EP (1) | EP1488228A4 (en) |
AU (1) | AU2003213786A1 (en) |
CA (1) | CA2478605A1 (en) |
WO (1) | WO2003076928A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005118806A2 (en) | 2004-05-28 | 2005-12-15 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
WO2008036776A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
EP2281888A1 (en) | 2004-11-12 | 2011-02-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
US20110307475A1 (en) * | 2010-06-15 | 2011-12-15 | Sas Institute Inc. | Techniques to find percentiles in a distributed computing environment |
WO2012005572A1 (en) | 2010-07-06 | 2012-01-12 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
WO2012068400A2 (en) | 2010-11-17 | 2012-05-24 | Asuragen, Inc. | Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
EP2487240A1 (en) | 2006-09-19 | 2012-08-15 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2012158238A2 (en) | 2011-02-28 | 2012-11-22 | University Of Iowa Research Foundation | Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
WO2013063544A1 (en) | 2011-10-27 | 2013-05-02 | Asuragen, Inc. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
WO2013063519A1 (en) | 2011-10-26 | 2013-05-02 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
WO2014007623A1 (en) | 2012-07-03 | 2014-01-09 | Interna Technologies B.V. | Diagnostic portfolio and its uses |
WO2014055117A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
WO2014145612A1 (en) | 2013-03-15 | 2014-09-18 | Ajay Goel | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
WO2014151551A1 (en) | 2013-03-15 | 2014-09-25 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
US9080215B2 (en) | 2007-09-14 | 2015-07-14 | Asuragen, Inc. | MicroRNAs differentially expressed in cervical cancer and uses thereof |
EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
EP3404116A1 (en) | 2013-03-15 | 2018-11-21 | The University of Chicago | Methods and compositions related to t-cell activity |
WO2019086603A1 (en) | 2017-11-03 | 2019-05-09 | Interna Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
WO2020210521A2 (en) | 2019-04-12 | 2020-10-15 | The Regents Of The University Of California | Compositions and methods for increasing muscle mass and oxidative metabolism |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9201916B2 (en) * | 2012-06-13 | 2015-12-01 | Infosys Limited | Method, system, and computer-readable medium for providing a scalable bio-informatics sequence search on cloud |
KR101624014B1 (en) | 2013-10-31 | 2016-05-25 | 가천대학교 산학협력단 | Genes selection method and system using fussy neural network |
CN109889981B (en) * | 2019-03-08 | 2020-11-06 | 中南大学 | Positioning method and system based on binary classification technology |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6160104A (en) * | 1998-10-13 | 2000-12-12 | Incyte Pharmaceuticals, Inc. | Markers for peroxisomal proliferators |
US6160105A (en) * | 1998-10-13 | 2000-12-12 | Incyte Pharmaceuticals, Inc. | Monitoring toxicological responses |
US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
US6221600B1 (en) * | 1999-10-08 | 2001-04-24 | Board Of Regents, The University Of Texas System | Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis |
US6303301B1 (en) * | 1997-01-13 | 2001-10-16 | Affymetrix, Inc. | Expression monitoring for gene function identification |
US6331396B1 (en) * | 1998-09-23 | 2001-12-18 | The Cleveland Clinic Foundation | Arrays for identifying agents which mimic or inhibit the activity of interferons |
US6340565B1 (en) * | 1998-11-03 | 2002-01-22 | Affymetrix, Inc. | Determining signal transduction pathways |
US6351712B1 (en) * | 1998-12-28 | 2002-02-26 | Rosetta Inpharmatics, Inc. | Statistical combining of cell expression profiles |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003033742A1 (en) * | 2001-10-17 | 2003-04-24 | University Of Utah Research Foundation | Methods for identifying differentially expressed genes by multivariate analysis of microarry data |
-
2003
- 2003-03-07 US US10/506,767 patent/US20060088831A1/en not_active Abandoned
- 2003-03-07 WO PCT/US2003/007103 patent/WO2003076928A1/en not_active Application Discontinuation
- 2003-03-07 CA CA002478605A patent/CA2478605A1/en not_active Abandoned
- 2003-03-07 AU AU2003213786A patent/AU2003213786A1/en not_active Abandoned
- 2003-03-07 EP EP03711477A patent/EP1488228A4/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303301B1 (en) * | 1997-01-13 | 2001-10-16 | Affymetrix, Inc. | Expression monitoring for gene function identification |
US6331396B1 (en) * | 1998-09-23 | 2001-12-18 | The Cleveland Clinic Foundation | Arrays for identifying agents which mimic or inhibit the activity of interferons |
US6160104A (en) * | 1998-10-13 | 2000-12-12 | Incyte Pharmaceuticals, Inc. | Markers for peroxisomal proliferators |
US6160105A (en) * | 1998-10-13 | 2000-12-12 | Incyte Pharmaceuticals, Inc. | Monitoring toxicological responses |
US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
US6340565B1 (en) * | 1998-11-03 | 2002-01-22 | Affymetrix, Inc. | Determining signal transduction pathways |
US6351712B1 (en) * | 1998-12-28 | 2002-02-26 | Rosetta Inpharmatics, Inc. | Statistical combining of cell expression profiles |
US6221600B1 (en) * | 1999-10-08 | 2001-04-24 | Board Of Regents, The University Of Texas System | Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis |
Non-Patent Citations (1)
Title |
---|
See also references of EP1488228A4 * |
Cited By (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2471924A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
EP2290068A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2065466A2 (en) | 2004-05-28 | 2009-06-03 | Asuragen, Inc. | Methods and compositions involving MicroRNA |
EP2471921A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
US10047388B2 (en) | 2004-05-28 | 2018-08-14 | Asuragen, Inc. | Methods and compositions involving MicroRNA |
WO2005118806A2 (en) | 2004-05-28 | 2005-12-15 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
EP2471923A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2474616A1 (en) | 2004-05-28 | 2012-07-11 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2471922A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290075A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290069A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290074A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290072A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290070A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290076A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290067A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290071A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290066A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP2290073A2 (en) | 2004-05-28 | 2011-03-02 | Asuragen, Inc. | Methods and compositions involving microRNA |
US8946177B2 (en) | 2004-11-12 | 2015-02-03 | Mima Therapeutics, Inc | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2281887A1 (en) | 2004-11-12 | 2011-02-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2292756A1 (en) | 2004-11-12 | 2011-03-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2298893A1 (en) | 2004-11-12 | 2011-03-23 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2298894A1 (en) | 2004-11-12 | 2011-03-23 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2302056A1 (en) | 2004-11-12 | 2011-03-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2302051A1 (en) | 2004-11-12 | 2011-03-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2302054A1 (en) | 2004-11-12 | 2011-03-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2302052A1 (en) | 2004-11-12 | 2011-03-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2302055A1 (en) | 2004-11-12 | 2011-03-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2302053A1 (en) | 2004-11-12 | 2011-03-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2314688A1 (en) | 2004-11-12 | 2011-04-27 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2322616A1 (en) | 2004-11-12 | 2011-05-18 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2808390A1 (en) | 2004-11-12 | 2014-12-03 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9051571B2 (en) | 2004-11-12 | 2015-06-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2292755A1 (en) | 2004-11-12 | 2011-03-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2281888A1 (en) | 2004-11-12 | 2011-02-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2808389A1 (en) | 2004-11-12 | 2014-12-03 | Asuragen, Inc. | Methods and compositions involving MIRNA and MIRNA inhibitor molecules |
US9068219B2 (en) | 2004-11-12 | 2015-06-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9506061B2 (en) | 2004-11-12 | 2016-11-29 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2287303A1 (en) | 2004-11-12 | 2011-02-23 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2281886A1 (en) | 2004-11-12 | 2011-02-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2284265A1 (en) | 2004-11-12 | 2011-02-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9447414B2 (en) | 2004-11-12 | 2016-09-20 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2281889A1 (en) | 2004-11-12 | 2011-02-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9382537B2 (en) | 2004-11-12 | 2016-07-05 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2487240A1 (en) | 2006-09-19 | 2012-08-15 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2008036776A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
US9080215B2 (en) | 2007-09-14 | 2015-07-14 | Asuragen, Inc. | MicroRNAs differentially expressed in cervical cancer and uses thereof |
US9365852B2 (en) | 2008-05-08 | 2016-06-14 | Mirna Therapeutics, Inc. | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
EP3214174A1 (en) | 2010-03-04 | 2017-09-06 | InteRNA Technologies B.V. | A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt |
WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
US20110307475A1 (en) * | 2010-06-15 | 2011-12-15 | Sas Institute Inc. | Techniques to find percentiles in a distributed computing environment |
US8949249B2 (en) * | 2010-06-15 | 2015-02-03 | Sas Institute, Inc. | Techniques to find percentiles in a distributed computing environment |
WO2012005572A1 (en) | 2010-07-06 | 2012-01-12 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
EP3369817A1 (en) | 2010-07-06 | 2018-09-05 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway |
WO2012068400A2 (en) | 2010-11-17 | 2012-05-24 | Asuragen, Inc. | Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms |
EP2772550A1 (en) | 2010-11-17 | 2014-09-03 | Asuragen, Inc. | MiRNAs as biomarkers for distinguishing benign from malignant thyroid neoplasms |
WO2012096573A1 (en) | 2011-01-11 | 2012-07-19 | Interna Technologies B.V. | Mirna for treating diseases and conditions associated with neo-angiogenesis |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
WO2012158238A2 (en) | 2011-02-28 | 2012-11-22 | University Of Iowa Research Foundation | Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
US10655184B2 (en) | 2011-09-13 | 2020-05-19 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
WO2013063519A1 (en) | 2011-10-26 | 2013-05-02 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
WO2013063544A1 (en) | 2011-10-27 | 2013-05-02 | Asuragen, Inc. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
WO2014007623A1 (en) | 2012-07-03 | 2014-01-09 | Interna Technologies B.V. | Diagnostic portfolio and its uses |
WO2014055117A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
WO2014151551A1 (en) | 2013-03-15 | 2014-09-25 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
EP3366785A2 (en) | 2013-03-15 | 2018-08-29 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
EP3404116A1 (en) | 2013-03-15 | 2018-11-21 | The University of Chicago | Methods and compositions related to t-cell activity |
WO2014145612A1 (en) | 2013-03-15 | 2014-09-18 | Ajay Goel | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
EP4163387A1 (en) | 2013-03-15 | 2023-04-12 | The University of Chicago | Methods and compositions related to t-cell activity |
WO2019086603A1 (en) | 2017-11-03 | 2019-05-09 | Interna Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
WO2020210521A2 (en) | 2019-04-12 | 2020-10-15 | The Regents Of The University Of California | Compositions and methods for increasing muscle mass and oxidative metabolism |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
Also Published As
Publication number | Publication date |
---|---|
EP1488228A4 (en) | 2008-09-17 |
AU2003213786A1 (en) | 2003-09-22 |
US20060088831A1 (en) | 2006-04-27 |
EP1488228A1 (en) | 2004-12-22 |
CA2478605A1 (en) | 2003-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003076928A1 (en) | Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis | |
Asyali et al. | Gene expression profile classification: a review | |
Ooi et al. | Genetic algorithms applied to multi-class prediction for the analysis of gene expression data | |
US8515680B2 (en) | Analysis of transcriptomic data using similarity based modeling | |
EP2387758B1 (en) | Evolutionary clustering algorithm | |
Ringnér et al. | Analyzing array data using supervised methods | |
Simon | Supervised analysis when the number of candidate features (p) greatly exceeds the number of cases (n) | |
WO2009130663A1 (en) | Classification of sample data | |
Szabo et al. | Multivariate exploratory tools for microarray data analysis | |
Simon | Using DNA microarrays for diagnostic and prognostic prediction | |
Gu et al. | Role of gene expression microarray analysis in finding complex disease genes | |
Huang et al. | Gene expression profiling for prediction of clinical characteristics of breast cancer | |
Horaira et al. | Colon cancer prediction from gene expression profiles using kernel based support vector machine | |
Park et al. | Evolutionary ensemble classifier for lymphoma and colon cancer classification | |
US20040265830A1 (en) | Methods for identifying differentially expressed genes by multivariate analysis of microaaray data | |
US20070275400A1 (en) | Multivariate Random Search Method With Multiple Starts and Early Stop For Identification Of Differentially Expressed Genes Based On Microarray Data | |
Mary-Huard et al. | Introduction to statistical methods for microarray data analysis | |
Chen et al. | Gene expression analyses using genetic algorithm based hybrid approaches | |
Otto | Distance-based methods for the analysis of Next-Generation sequencing data | |
Asyali | Gene expression profile class prediction using linear Bayesian classifiers | |
Kim | Statistical learning methods for multi-omics data integration in dimension reduction, supervised and unsupervised machine learning | |
Ando et al. | An approach based on clustering for detecting differentially expressed genes in microarray data analysis | |
Ramamoorthy | Critical Review of Methods available for Microarray Data Analysis | |
Horvath et al. | Statistical methods supplement and R software tutorial: Gene filtering with a random forest predictor | |
Raza et al. | Comparative study of multivariate classification methods using microarray gene expression data for BRCA1/BRCA2 cancer tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2478605 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003711477 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003711477 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006088831 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10506767 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10506767 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |